TNF-α Antibody, anti-human, REAfinity™
Synonyms: Tumor necrosis factor, Cachectin, TNF-alpha, TNF-a, DIF-alpha, TNFa, TNFSF2
RECOMBINANT EXTENDED VALIDATION
Bioz Star95/100 Bioz rating
33 Citations3 Images
Clone:
REA656 | cA2
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for TNF-α Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
FITC
PE-Vio 770
Vio B515
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left images) or stimulated with 20 ng/mL PMA and 1 µg/mL ionomycin for 6 hours and after 2 hours with 1 µg/mL brefeldin A for 4 hours. Cells were then fixed, permeabilized, and stained with Anti-TNF-α antibodies as well as with CD69 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. CD4+ cells were pre-gated for the analysis. Cell debris were excluded from the analysis based on scatter signals.
Intracellular flow cytometry applications
APC
FITC
PE
PE-Vio 770
Vio B515
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-120-063, 130-120-149
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left images) or stimulated with 20 ng/mL PMA and 1 µg/mL ionomycin for 6 hours and after 2 hours with 1 µg/mL brefeldin A for 4 hours. Cells were then fixed, permeabilized, and stained with Anti-TNF-α antibodies as well as with CD69 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. CD4+ cells were pre-gated for the analysis. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
Extended validation for TNF-α Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA656
CA2
high
Mab11
++
357-167-24
low

Cells were incubated with an excess of purified unconjugated TNF-α (REA656) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for TNF-α. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL brefeldin A for 4 hours. Cells were stained with a suitable counterstaining and then fixed and permeabilized followed by a staining with TNF-α antibodies. As a control, TNF-α antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD3+/CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for TNF-α Antibody, anti-human, REAfinity™
Overview

Clone REA656 recognizes the human tumor necrosis factor alpha (TNF-α) antigen, which is a cytokine involved in inflammatory immune responses. TNF-α has different functions, it plays an important role in the regulation of immune cells and is a potent pyrogen causing fever and apoptotic cell death. Furthermore, the TNF intracellular domain form is able to induce interleukin 12 (IL-12) production in dendritic cells. TNF-α is secreted by activated CD4+ T cells, monocytes, macrophages, natural killer (NK) cells, mast cells, eosinophils, and neutrophils.

Additional information: Clone REA656 displays negligible binding to Fc receptors.

Alternative names

Tumor necrosis factor, Cachectin, TNF-alpha, TNF-a, DIF-alpha, TNFa, TNFSF2

Detailed product information

Technical specifications

Clone
REA656
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
TNF-α
Molecular mass of antigen [kDa]
26
Distribution of antigen
T cells, monocytes, macrophages, NK cells, mast cells, eosinophils, neutrophils
Entrez Gene ID
RRID
AB_2752014, AB_2751984, AB_2751595, AB_2905445, AB_2905447, AB_2922016, AB_2905446, AB_2751641, AB_2921998, AB_2905444

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for TNF-α Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support